Kokron O, Micksche M, Titscher R, Wrba H
Onkologie. 1982 Apr;5(2):56-9. doi: 10.1159/000214968.
55 selected patients with inoperable small cell carcinoma of the lung have been induced in a randomized prospective trial in order to compare the efficacy of ifosfamide monotherapy with the combination of ifosfamid + CCNU. Initially a control group, treated with symptomatic therapy only, was also included but preliminary analysis revealing that results were unfavourable in comparison to those of the chemotherapy group; this treatment arm was omitted. 53 of 55 patients were evaluable. In group 1 (symptomatic therapy) results were better as to patients' quality of life, but no tumor remissions have been observed and survival times were significantly shorter (15 to 122 days; geometric mean 42.35 days). In group 2 (ifosfamide monotherapy) one total remission (lasting 15 months) and 2 partial remissions (lasting from 3 weeks to 4 months) have been achieved; in this group survival was 3 to 473 days (geometric mean 110.15 days). In group 3 (ifosfamide + CCNU) 7 partial remissions have been observed (3 weeks to 4 months), survival was 17 to 477 days (geometric mean 107.32 days). The combination of ifosfamide with CCNU did not reveal any advantage in comparison to ifosfamide monotherapy.
55例无法手术的肺小细胞癌患者参与了一项随机前瞻性试验，以比较异环磷酰胺单药治疗与异环磷酰胺 + 洛莫司汀联合治疗的疗效。最初还纳入了仅接受对症治疗的对照组，但初步分析显示，与化疗组相比，该组结果不佳，因此该治疗组被剔除。55例患者中有53例可进行评估。在第1组（对症治疗组），患者的生活质量较好，但未观察到肿瘤缓解，生存时间明显较短（15至122天；几何均数42.35天）。在第2组（异环磷酰胺单药治疗组），有1例完全缓解（持续15个月）和2例部分缓解（持续3周至4个月）；该组的生存时间为3至473天（几何均数110.15天）。在第3组（异环磷酰胺 + 洛莫司汀组），观察到7例部分缓解（3周至4个月），生存时间为17至477天（几何均数107.32天）。与异环磷酰胺单药治疗相比，异环磷酰胺与洛莫司汀联合治疗未显示出任何优势。
